Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.2B | 2M | 2M | 2M | 4M |
| Gross Profit | 1.3B | 1M | 971K | 1M | 2M |
| Operating Income | -2M | -3M | -4M | -3M | -2M |
| EBITDA | -2M | -3M | -4M | -3M | -2M |
| Net Income | -2M | -3M | -4M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Consumer Defensive
Live Price
Offline$0.07
+0.00% today
1Y Change
-36.36%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PURE Bioscience, Inc. (PURE) is a Consumer Defensive stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.07 and down 36.4% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +112075.2%, EPS growth of +28.4%, a dividend yield of 0.0%. What stands out right now is revenue +112075.2%, EPS +28.4%, free cash flow -79512.8% with operating margin -82.3% and ROIC 1548.4%. Valuation is more restrained than many high-expectation growth names at price/sales 3.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PURE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Consumer Defensive peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PURE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PURE Max Drawdown
-63.64%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PURE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.9M
+111.9% YoY
FY Net Income
-$2.3M
+33.7% YoY
Free Cash Flow
-$1.7M
+32.5% YoY
Revenue Growth
+112075.2%
EPS Growth
+28.4%
Gross Margin
54139.4%
Net Margin
-89.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.2B | 2M | 2M | 2M | 4M |
| Gross Profit | 1.3B | 1M | 971K | 1M | 2M |
| Operating Income | -2M | -3M | -4M | -3M | -2M |
| EBITDA | -2M | -3M | -4M | -3M | -2M |
| Net Income | -2M | -3M | -4M | -3M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 334M | 349K | 1M | 3M | 2M |
| Total Assets | 1.1B | 818K | 2M | 4M | 4M |
| Total Liabilities | 6.2B | 4M | 2M | 575K | 970K |
| Shareholder Equity | -5.1B | -3M | 272K | 4M | 3M |
| Total Debt | 5.2B | 3M | 1M | 0 | 239K |
| Net Debt | 4.9B | 3M | -74K | -3M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
+51.7% YoY
Capital Expenditures
521K
-543.2% YoY
Free Cash Flow
2M
+32.5% YoY
Key ratios
Gross Margin
54139.4%
Operating Margin
-82.3%
Net Margin
-89.8%
ROE
39.7%
Debt / Equity
-0.98x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.